ClinicalTrials.Veeva

Menu

Frequency Of Eye Problems In Type 2 Diabetes With Chronic Kidney Disease

M

Mohammed Ramadan Abdallah

Status

Unknown

Conditions

Renal Impairment
Type2 Diabetes
Eye Diseases

Treatments

Device: fundoscope

Study type

Observational

Funder types

Other

Identifiers

NCT03330054
AssiutU MRAbdallah

Details and patient eligibility

About

This study evaluate the frequency and type of eye problem among Type 2 Diabetics with renal impairment and effect of renal impairment and haemodialysis on diabetic retinopathy

Full description

Chronic kidney disease is a descriptive term and is used for deteriorating kidney function of any underlying cause. Chronic kidney disease implies longstanding (>3 months), potentially progressive, impairment in renal function.(Kumar & Clark's ., 2016).

Diabetes mellitus is the most common cause of chronic kidney disease in developed countries. In patients with diabetes, there is a steady advance from microalbuminuria to dipstick positive proteinuria and a progression to renal failure. (Davidson's.,2014) .The most commonly diagnosed diabetes-related complications is diabetic retinopathy. Its prevalence increases with the duration of diabetes. Some 20%of people with type 1 diabetes will have retinal changes after 10 years, rising to >95% after20 years; 20-30% of people with type 2 diabetes have retinopathy at diagnosis.(Kumar & Clark's ., 2016) .

Also from risk factors of diabetic retinopathy is nephropathy, and if severe, is associated with worsening of Diabetic retinopathy. Conversely, treatment of renal disease (e.g. renal transplantation) may be associated with improvement of retinopathy and a better response to photocoagulation.(Kanaski ,2016) The high burden of ocular disease in Chronic kidney disease can be explained, in part, by the sharing of risk factors common to both kidney and eye diseases such as age, smoking, hypertension, diabetes, raised serum cholesterol and obesity. Ocular diseases may also be directly linked to chronic kidney disease via common pathogenic pathways, including, atherosclerosis, microangiopathy, inflammation and oxidative stress (Wong et al., 2014).

In our study we seek to do the following for participants :

  1. A detailed history including

    1. Age, sex, smoking Habits
    2. Duration of diabetes mellitus and treatment.
    3. Chronic kidney disease stage by estimated glomerular filtration rate according to MDRD formula
    4. Duration of haemodialysis.
    5. Associated co-morbidity as hypertension,
    6. Therapeutic history eg; angiotensin converting enzyme, angiotensin II receptor blocker, amiodarone, erythropoietin.
  2. Complete Clinical examination including haemodynamics, complete cardiac, chest, abdominal, lower limb examination, cranial nerve examination.

  3. Complete eye examination including detailed fundus examination, classifying expected eye problems as:

    • Cataract. - Glaucoma
    • Cranial nerve affection
    • Retinopathy either proliferative, non proliferative or macular oedema.
  4. The following investigations will be done:

    • Serum creatinine & Blood Urea for estimation of glomerular filtration rate
    • Glycated haemoglobin (HbA1c).
    • lipogram.
    • Complete blood count
    • ECG

Enrollment

100 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 50 patients Type 2 Diabetes without renal impairment.
  • 25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy. (stage I-IV)
  • 25 patients Type 2 Diabetes with end-stage renal disease on haemodialysis

Exclusion criteria

  • patients with previous history of eye problems and any systemic disease.
  • Type 1 Diabetics .
  • Acute kidney injury in Diabetics.

Trial design

100 participants in 3 patient groups

Group A
Description:
50 patients Type 2 Diabetes without renal impairment will be examined using fundoscope
Treatment:
Device: fundoscope
Group B
Description:
25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy (stage I-IV) will be examined using fundoscope
Treatment:
Device: fundoscope
Group C
Description:
25 patients Type 2 Diabetes with end stage renal disease on haemodialysis will be examined using fundoscope
Treatment:
Device: fundoscope

Trial contacts and locations

0

Loading...

Central trial contact

Mohamed R Abdallah

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems